CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

Rhea-AI Summary

CASI Pharmaceuticals (NASDAQ: CASI) announced the filing of its annual report on Form 20-F for the fiscal year ending December 31, 2022, with the U.S. Securities and Exchange Commission on April 26, 2023. The report highlights the company's ongoing commitment to developing innovative therapeutics in hematology oncology and other unmet medical needs. Shareholders can request a free hard copy of the audited consolidated financial statements. The company aims to establish a strong presence in the Greater China market, leveraging its regulatory and commercial competencies alongside its global drug development expertise. More details are available on the company's investor relations website.

Positive

• Focus on innovative therapeutics in hematology oncology.
• Strong operational base in the Greater China market.
• Over 100 sales and marketing specialists in China.

Negative

• None.

BEIJING, April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission ("SEC") on April 26, 2023. The annual report can be accessed on the Company's investor relations website at https://www.casipharmaceuticals.com/investor-relations/ as well as the SEC's website at https://www.sec.gov/.

The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations Department, CASI Pharmaceuticals, Inc., Rm 1701-1702, China Central Office Tower 1, No.81 Jianguo Road Chaoyang District, Beijing, 100025, China.

About CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market, leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China. The Company has built a commercial team of more than 100 hematology and oncology sales and marketing specialists based in China. More information on CASI is available at www.casipharmaceuticals.com.

For more information, please contact:

Company Contact: 
CASI Pharmaceuticals, Inc. 
Rui Zhang 
240-864-2643 
ir@casipharmaceuticals.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-files-annual-report-on-form-20-f-for-fiscal-year-2022-301808180.html

SOURCE CASI Pharmaceuticals, Inc.

FAQ

What did CASI Pharmaceuticals announce on April 26, 2023?

CASI Pharmaceuticals announced the filing of its annual report on Form 20-F for the fiscal year ending December 31, 2022.

Where can I access CASI Pharmaceuticals' annual report?

The annual report can be accessed on CASI's investor relations website and the SEC's website.

What is CASI Pharmaceuticals' focus in the biopharmaceutical industry?

CASI Pharmaceuticals focuses on developing and commercializing innovative therapeutics, particularly in hematology oncology and other areas of unmet medical need.

How many sales and marketing specialists does CASI Pharmaceuticals have in China?

CASI Pharmaceuticals has built a commercial team of over 100 hematology and oncology sales and marketing specialists in China.